News
News Center
2019-10-16
In 2019, there were 22 key special projects under the "Stem Cells and Translational Research" program, with total funding of 367 million yuan.
+
2019-09-25
On September 24, 2019, the official website of the Ministry of Science and Technology released a notice seeking feedback on the 2020 project application guidelines for seven key special projects under the National Key R&D Program, including "Stem Cells and Translational Research." In 2020, priority will be given to supporting nine specific research areas. The total national funding allocated is 230 million yuan, with up to 36 million yuan earmarked for six projects aimed at young scientists.
+
2019-09-23
China's 9th Annual Stem Cell Conference Held in Tianjin
Stem Cell Research and Translation: Ready to Revolutionize—Jiuzhitang Maker is committed to becoming China's pioneer and leader in stem-cell-based pharmaceuticals!
+
2019-09-12
During the forum, Li Zhenguo, President of Jiuzhitang Group and Chairman of Jiuzhitang Co., Ltd., along with Milan from Kazakhstan’s ALTACO Company, jointly unveiled the Jiuzhitang-ALTACO International Medical Center, witnessed by attendees of the event. This marks the official establishment of the center within the China-Kazakhstan Khorgos Border Cooperation Center.
+
2019-09-12
Economic Daily – China Economic Net, Khorgos, September 7: On September 7, the China-Kazakhstan Medical and Healthcare Industry Summit Forum was held. Li Zhenguo, Chairman of Jiuzhitang Co., Ltd., emphasized at the Belt and Road Initiative Summit on Traditional Medicine and Regenerative Medicine that China should fully leverage the advantages of traditional Chinese medicine to foster cooperation in the medical and healthcare sectors along the Belt and Road countries. At the same time, by integrating traditional Chinese medicine with Western medical approaches, we can draw on cutting-edge global medical advancements, ultimately providing comprehensive, life-cycle health management solutions for people living along the Belt and Road routes.
+
2019-08-27
Support eligible medical and healthcare institutions within the free trade pilot zone to carry out cutting-edge clinical research projects on stem cells, in accordance with relevant regulations, and establish a streamlined green channel for project registration.
+
2019-08-27
Liu Pei, Director of the Department of Policies and Regulations at the National Medical Products Administration, stated that the General Provisions of the Drug Administration Law clearly stipulate the state's commitment to encouraging research and development of new drugs, while also introducing and enhancing a range of institutional measures aimed at fostering innovation and accelerating the availability of novel medicines on the market.
+
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy